 |
|
|
| |
FALDAPREVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONIC HCV GENOTYPE-1 TREATMENT-NAIVE PATIENTS
|
| |
| |
Reported by Jules Levin
EASL 2013 Amsterdam April 27, 2013
Ferenci P1, Asselah T2, Foster GR3, Zeuzem S4, Sarrazin C4,
Moreno C5, Ouzan D6, Maevskaya M7, Calinas F8, Morano LE9,
Crespo J10, DufourJ-F11, Bourliere M12, Agarwal K13, Forton D14, Schuchmann M15, Zehnter E16, Nishiguchi S17, Omata M18, Stern J19, Datzenko Y20, Scherer J19, Quinson AM19
1Medical University of Vienna, Vienna, Austria; 2Hepatology Department, Beaujon Hospital, AP-HP, University Paris Diderot 7 and INSERM U773, CRB3, Clichy, France; 3Queen Mary, University of London, London, UK; 4JW Goethe University Hospital, Frankfurt, Germany; 5Hôpital Universitaire Erasme, Brussels, Belgium; 6Institut Arnault Tzanck, St Laurent du Var, France; 7First Moscow State Medical University, Moscow, Russia; 8Centro Hospitalar de Lisboa Central, Lisbon, Portugal; 9Hospital Meixoeiro, Vigo, Spain; 10Hospital Univ. De Valdecilla, Santander, Spain; 11Universitätsklinik für Viszerale Chirurgie und Medizin, Bern, Switzerland; 12Hopital Saint Joseph, Marseille, France; 13King's College Hospital, London, UK; 14St George's Hospital, London, UK; 15University Hospital Mainz, Mainz, Germany; 16Schwerpunktpraxis Hepatologie, Dortmund, Germany; 17Hyogo College of Medicine, Hyogo, Japan; 18Yamanashi Central and Kita Hospitals, Yamanashi, Japan; 19Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA; 20Boehringer Ingelheim Pharmaceuticals GmbH & Co KG, Biberach, Germany
|
| |
|
|
|
|
|
